According to the National Cancer Registry, the lifetime risk for prostate cancer in men in South Africa is one in 18.
While these statistics are scary, the good news is that prostate cancer tools and treatments are becoming more advanced by the minute!
The latest tool that researchers have developed is a validated genetic tool to predict aggressive prostate cancer onset. Read on to learn all about it.
Researchers have developed a tool that predicts aggressive prostate cancer
Research carried out by an international team headed up by University of California San Diego School of Medicine scientists referenced the tool may potentially be used to help guide decisions about who should screen for prostate cancer
and at what age.
The work involved the team from Europe, Australia and the United States using genome-wide association studies (GWAS) to determine if a man’s genetic disposition to developing prostate cancer
could also predict his risk of developing an aggressive, lethal form of prostate cancer
Officials said that the results of the research led to a polygenic hazard score for prostate
cancer that can estimate the genetic risk of individual men. They added that further study of the clinical benefits are needed before the polygenic hazard score is ready for routine use.
The healing secret big pharma doesn’t want you to know!
“I may be politically incorrect and stepping on the toes of big pharma, but, my test results for my aggressive prostate cancer in consistently getting better and better. I have gone from surgery, chemo and radiation suggestions to my doctor’s suggestion of wait-and-see, as improvement has been quite dramatic. I have only been on my daily regimen for 9 months.” ~ John Duffy
Click here to find out what is healing John.
Prostate cancer detection currently relies primarily upon the PSA screening blood test
Officials point out that current prostate cancer detection relies heavily upon the prostate-specific antigen (PSA) screening blood test. Many doctors around the world acknowledge that PSA testing isn’t a very good screening. While PSA reduces prostate cancer deaths, it can produce false positive results and encourage over-detection of non-aggressive, slow-growing tumours in the prostate.
“The existing PSA test is useful, but it is not precise enough to be used indiscriminately on all men,” said Tyler M Seibert, first author of the study and chief resident physician in the Department of Radiation Medicine and Applied Sciences at UC San Diego School of Medicine. “As a result, it may prompt medical interventions like biopsy, surgery or radiotherapy that might not be necessary,” added Seibert.
For more information on this prostate cancer detection tool, have a chat with your doctor.
Note: 3.5 of 3 votes